Stock Market Today: Hims & Hers Tumbles 12% on Revenue Miss Despite 73% Growth

Hims & Hers Health (HIMS) shares fell 12.36% to $55.52 on high volume after its second-quarter revenue of $544.8 million, a 73% year-over-year increase, narrowly missed analyst expectations, triggering a sharp sell-off. This occurred despite the company beating net income forecasts with $42.5 million and more than doubling adjusted EBITDA to $82.2 million, alongside robust subscriber growth. The stock's premium valuation and negative free cash flow likely amplified the decline, though management reaffirmed full-year guidance and outlined future expansion into new health services.

Analysis

Hims & Hers Health (HIMS) experienced a significant sell-off, with its stock declining 12.36% on volume more than double its three-month average, pushing the shares nearly 24% below their recent high. The catalyst for this sharp reaction was a second-quarter revenue figure of $544.8 million which, despite representing robust 73% year-over-year growth, narrowly missed analyst expectations. This revenue miss overshadowed otherwise strong fundamentals, including a net income beat of $42.5 million and a doubling of adjusted EBITDA to $82.2 million. The company's underlying operational health appears solid, evidenced by a 31% increase in subscribers to 2.4 million and a 30% rise in average monthly revenue per user to $74. However, the market's severe response is contextualized by the stock's premium valuation, indicated by a P/E ratio of 81, and its negative free cash flow. These factors suggest a low tolerance among investors for any operational shortfalls. The sell-off was largely company-specific, as peers Teladoc and Option Care Health saw only marginal declines. In response, management reaffirmed full-year guidance and pointed to future growth from expansion into new health verticals, signaling confidence in its long-term strategy despite the short-term market turbulence.

Key Decisions for Investors

• Investors should weigh the company's strong operational metrics, such as 73% revenue growth and rising user monetization, against the significant risks posed by its high P/E ratio of 81 and negative free cash flow, which make the stock highly vulnerable to any future guidance misses.
• The sharp, high-volume sell-off following a minor revenue miss could represent a buying opportunity for long-term investors who are confident in management's reaffirmed full-year guidance and expansion strategy.
• It is crucial to monitor the company's ability to meet its upcoming quarterly targets and demonstrate a clear path to achieving positive free cash flow, as these will be key catalysts for rebuilding investor confidence and justifying its premium valuation.